SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00595517

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use

The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs.

NCT00595517 Gastric Ulcer Duodenal Ulcer Rheumatoid Arthritis Osteoarthritis Lumbago
MeSH:Stomach Ulcer Duodenal Ulcer Ulcer
HPO:Duodenal ulcer Gastric ulcer

1 Interventions

Name: Esomeprazole 20 mg

Description: Esomeprazole 20 mg once daily
Type: Drug
Group Labels: 1

Esomeprazole 20 mg


Primary Outcomes

Measure: Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period

Time: up to 52 weeks

Secondary Outcomes

Measure: Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

Time: up to 4 weeks after treatment

Measure: Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

Time: up to 12 weeks after treatment

Measure: Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment

Time: up to 24 weeks after treatment

Purpose: Prevention

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 D961H

A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use. --- D961H ---

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs. --- D961H ---

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs. --- D961H --- --- D961H ---



HPO Nodes


HPO: